IMMUTEP Ltd
Developing LAG-3-based immunotherapies for cancer and autoimmune diseases.
IMMP | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE, SYDNEY,
- Website:
- https://www.immutep.com/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Immutep Ltd is a late clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and autoimmune diseases. A pioneer in the field, the company focuses on therapeutics related to the Lymphocyte Activation Gene-3 (LAG-3), a key immune control mechanism. Its diversified pipeline harnesses LAG-3's ability to either stimulate the immune response to combat cancer or modulate it to treat autoimmune conditions. Immutep's portfolio consists of four clinical-stage assets targeting areas of high unmet medical need.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all IMMUTEP Ltd filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for IMMUTEP Ltd
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for IMMUTEP Ltd via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
